CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab

被引：2

作者：

Gambardella, Alessio ^{[1
]}

Licata, Gaetano ^{[1
]}

Calabrese, Giulia ^{[1
]}

De Rosa, Alina ^{[1
]}

Pagliuca, Francesca ^{[2
]}

Alfano, Roberto ^{[3
]}

Argenziano, Giuseppe ^{[1
]}

机构：

[1] Univ Campania Luigi Vanvitelli, Dept Mental & Phys Hlth & Prevent Med, Dermatol Unit, Naples, Italy

[2] Univ Campania Luigi Vanvitelli, Dept Mental & Phys Hlth & Prevent Med, Div Pathol, Naples, Italy

[3] Univ Campania Luigi Vanvitelli, Dept Anesthesiol Surg & Emergency, Naples, Italy

来源：

PSORIASIS-TARGETS AND THERAPY | 2020年 / 10卷

关键词：

immune-mediated inflammatory diseases; biological therapy; anti-TNF-alpha therapy; cytomegalovirus; psoriasis; case report;

D O I：

10.2147/PTT.S284701

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

The use of biological therapy is now common practice in the treatment of immune-mediated inflammatory diseases (IMID). Currently, there are no guidelines related to the management of cytomegalovirus (CMV) infections or reactivation during therapy with biological agents. Furthermore, there is a lack of guidance on the management of asymptomatic patients with persistent positive immunoglobulin (Ig)M anti-CMV after an extended period and who have to undergo therapy with biological agents. We report the case of a patient in this situation for whom treatment with biological drugs for psoriasis was indicated. A good clinical response was obtained with secukinumab and maintained during 6 months of follow-up. No infectious disease or reactivation of CMV infection occurred. We suggest some possible guidelines for the management of such cases.

引用

页码：57 / 60

页数：4

共 10 条

[1] Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5years of treatment (SCULPTURE Extension Study) [J].

Bissonnette, R. ;

Luger, T. ;

Thaci, D. ;

Toth, D. ;

Lacombe, A. ;

Xia, S. ;

Mazur, R. ;

Patekar, M. ;

Charef, P. ;

Milutinovic, M. ;

Leonardi, C. ;

Mrowietz, U. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (09) :1507-1514

[2] Cytomegalovirus Colitis in a Patient Treated with Efalizumab [J].

Caudron, Anne ;

Lok, Catherine ;

Clabaut, Angele ;

Desblache, Julien ;

Heyman, Bertrand ;

Viseux, Valerie .

DERMATOLOGY, 2009, 218 (01) :84-85

[3] The impact of long-term secukinumab treatment on Epstein-Barr virus and cytomegalovirus loads in patients with psoriasis [J].

Chiu, Hsien-Yi ;

Chan, Chih-Chieh ;

Tsai, Tsen-Fang .

INTERNATIONAL JOURNAL OF DERMATOLOGY, 2016, 55 (11) :E600-E602

[4]

Miquel FJ, 2009, ARCH DERMATOL, V145, P961, DOI 10.1001/archdermatol.2009.154

[5] Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' resume [J].

Krmpotic, Astrid ;

Podlech, Juergen ;

Reddehase, Matthias J. ;

Britt, William J. ;

Jonjic, Stipan .

MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2019, 208 (3-4) :415-429

[6] Risk of cytomegalovirus reactivation in patients with immune-mediated inflammatory diseases undergoing biologic treatment: a real matter? [J].

Mencarini, J. ;

Spinicci, M. ;

Bartalesi, F. .

REUMATISMO, 2016, 68 (03) :144-147

[7] Cytomegalovirus complicating biological immunosuppressive therapy in two patients with psoriasis receiving treatment with etanercept or efalizumab [J].

Petersen, Bibi ;

Lorentzen, Henrik .

ACTA DERMATO-VENEREOLOGICA, 2008, 88 (05) :523-524

[8]

Ross S A, 2011, Infect Disord Drug Targets, V11, P466

[9] Clinical aspects and management of cytomegalovirus infection [J].

Sissons, JGP ;

Carmichael, AJ .

JOURNAL OF INFECTION, 2002, 44 (02) :78-83

[10] Clinical evaluation of the Roche ElecsysA® CMV IgG Avidity assay [J].

Vauloup-Fellous, C. ;

Lazzarotto, T. ;

Revello, M. G. ;

Grangeot-Keros, L. .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2014, 33 (08) :1365-1369

← 1 →